Subpar reporting of pre‐analytical variables in RNA‐focused blood plasma studies
- Author
- Céleste Van Der Schueren (UGent) , Philippe Decruyenaere (UGent) , Francisco Avila Cobos (UGent) , Johanna Bult, Jill Deleu (UGent) , Lydia Dipalo, Hetty Helsmoortel (UGent) , Eva Hulstaert, Annelien Morlion (UGent) , Elena Ramos Varas (UGent) , Kathleen Schoofs (UGent) , Wim Trypsteen (UGent) , Eveline Vanden Eynde (UGent) , Hanne Van Droogenbroeck (UGent) , Kimberly Verniers (UGent) , Jo Vandesompele (UGent) and Anneleen Decock (UGent)
- Organization
- Project
-
- Implementation of a longitudinal multi-omics prediction model for response to immune checkpoint inhibition
- Therapy response monitoring in pediatric cancer basket trial patients
- Cancer-specific circulating RNAs as biomarkers for diagnosis and therapy response monitoring.
- Circulating tumor-derived RNA biomarkers: from bench to bedside
- Exploring the use of extracellular RNA in liquid biopsies for precision oncology purposes
- Cell-free nucleic acid profiling in diffuse large B-cell lymphoma: a molecular guidance to precision medicine
- Prostate cancer patient exosomes: where do they come from and where are they going?
- The role of exosomal non-coding RNAs in melanoma metastasis
- Cancer-specific circulating RNAs as biomarkers for diagnosis and therapy response monitoring
- The biology of tumor-derived extracellular RNA in liquid biopsies
- iPC (Individualized Paediatric Cure: Cloud-based virtual-patient models for precision paediatric oncology)
- Advancing Liquid Biopsies for Monitoring and Personalized Treatment of Children with Neuroblastoma
- Abstract
- Extracellular RNA (cell-free RNA; exRNA) from blood-derived liquid biopsies is an appealing, minimally invasive source of disease biomarkers. As pre-analytical variables strongly influence exRNA measurements, their reporting is essential for meaningful interpretation and replication of results. The aim of this review was to chart to what extent pre-analytical variables are documented, to pinpoint shortcomings and to improve future reporting. In total, 200 blood plasma exRNA studies published in 2018 or 2023 were reviewed for annotation of 22 variables associated with blood collection, plasma preparation, and RNA purification. Our results show that pre-analytical variables are poorly documented, with only three out of 22 variables described in over half of the publications. The percentage of variables reported ranged from 4.6% to 54.6% (mean 24.84%) in 2023 and from 4.6% to 57.1% (mean 28.60%) in 2018. Recommendations and guidelines (i.e., BRISQ, ASCO-CAP, BloodPAC, PPMPT, and CEN standards) have currently not resulted in improved reporting. In conclusion, our results highlight the lack of reporting pre-analytical variables in exRNA studies and advocate for a consistent use of available standards, endorsed by funders and journals.
- Keywords
- Cancer Research, Genetics, Molecular Medicine, General Medicine, Oncology, pre-analytical variable, plasma, liquid biopsies, extracellular RNA, circulating cell-free RNA, cell-free RNA
Downloads
-
Molecular Oncology - 2024 - Van Der Schueren - Subpar reporting of pre‐analytical variables in RNA‐focused blood plasma.pdf
- full text (Published version)
- |
- open access
- |
- |
- 901.54 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01HTHJTPCT8B7QZVYFWMQFMBVR
- MLA
- Van Der Schueren, Céleste, et al. “Subpar Reporting of Pre‐analytical Variables in RNA‐focused Blood Plasma Studies.” MOLECULAR ONCOLOGY, 2024, doi:10.1002/1878-0261.13647.
- APA
- Van Der Schueren, C., Decruyenaere, P., Avila Cobos, F., Bult, J., Deleu, J., Dipalo, L., … Decock, A. (2024). Subpar reporting of pre‐analytical variables in RNA‐focused blood plasma studies. MOLECULAR ONCOLOGY. https://doi.org/10.1002/1878-0261.13647
- Chicago author-date
- Van Der Schueren, Céleste, Philippe Decruyenaere, Francisco Avila Cobos, Johanna Bult, Jill Deleu, Lydia Dipalo, Hetty Helsmoortel, et al. 2024. “Subpar Reporting of Pre‐analytical Variables in RNA‐focused Blood Plasma Studies.” MOLECULAR ONCOLOGY. https://doi.org/10.1002/1878-0261.13647.
- Chicago author-date (all authors)
- Van Der Schueren, Céleste, Philippe Decruyenaere, Francisco Avila Cobos, Johanna Bult, Jill Deleu, Lydia Dipalo, Hetty Helsmoortel, Eva Hulstaert, Annelien Morlion, Elena Ramos Varas, Kathleen Schoofs, Wim Trypsteen, Eveline Vanden Eynde, Hanne Van Droogenbroeck, Kimberly Verniers, Jo Vandesompele, and Anneleen Decock. 2024. “Subpar Reporting of Pre‐analytical Variables in RNA‐focused Blood Plasma Studies.” MOLECULAR ONCOLOGY. doi:10.1002/1878-0261.13647.
- Vancouver
- 1.Van Der Schueren C, Decruyenaere P, Avila Cobos F, Bult J, Deleu J, Dipalo L, et al. Subpar reporting of pre‐analytical variables in RNA‐focused blood plasma studies. MOLECULAR ONCOLOGY. 2024;
- IEEE
- [1]C. Van Der Schueren et al., “Subpar reporting of pre‐analytical variables in RNA‐focused blood plasma studies,” MOLECULAR ONCOLOGY, 2024.
@article{01HTHJTPCT8B7QZVYFWMQFMBVR,
abstract = {{Extracellular RNA (cell-free RNA; exRNA) from blood-derived liquid biopsies is an appealing, minimally invasive source of disease biomarkers. As pre-analytical variables strongly influence exRNA measurements, their reporting is essential for meaningful interpretation and replication of results. The aim of this review was to chart to what extent pre-analytical variables are documented, to pinpoint shortcomings and to improve future reporting. In total, 200 blood plasma exRNA studies published in 2018 or 2023 were reviewed for annotation of 22 variables associated with blood collection, plasma preparation, and RNA purification. Our results show that pre-analytical variables are poorly documented, with only three out of 22 variables described in over half of the publications. The percentage of variables reported ranged from 4.6% to 54.6% (mean 24.84%) in 2023 and from 4.6% to 57.1% (mean 28.60%) in 2018. Recommendations and guidelines (i.e., BRISQ, ASCO-CAP, BloodPAC, PPMPT, and CEN standards) have currently not resulted in improved reporting. In conclusion, our results highlight the lack of reporting pre-analytical variables in exRNA studies and advocate for a consistent use of available standards, endorsed by funders and journals.}},
author = {{Van Der Schueren, Céleste and Decruyenaere, Philippe and Avila Cobos, Francisco and Bult, Johanna and Deleu, Jill and Dipalo, Lydia and Helsmoortel, Hetty and Hulstaert, Eva and Morlion, Annelien and Ramos Varas, Elena and Schoofs, Kathleen and Trypsteen, Wim and Vanden Eynde, Eveline and Van Droogenbroeck, Hanne and Verniers, Kimberly and Vandesompele, Jo and Decock, Anneleen}},
issn = {{1574-7891}},
journal = {{MOLECULAR ONCOLOGY}},
keywords = {{Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology,pre-analytical variable,plasma,liquid biopsies,extracellular RNA,circulating cell-free RNA,cell-free RNA}},
language = {{eng}},
pages = {{11}},
title = {{Subpar reporting of pre‐analytical variables in RNA‐focused blood plasma studies}},
url = {{http://doi.org/10.1002/1878-0261.13647}},
year = {{2024}},
}
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: